L1 Capital : “IQVIA Holdings (IQV) Expects to Deliver Consistent, Compounding Growth”

L1 Capital International, an investment management company, released its second quarter 2022 investor letter. A copy of the same can be downloaded here. The fund returned -10.1% net of fees in the second quarter compared to the benchmark return of -8.5%. Current macroeconomic issues and geopolitical situations affected the fund’s performance in the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

L1 Capital International discussed stocks like IQVIA Holdings Inc. (NYSE:IQV) in the second quarter investor letter. IQVIA Holdings Inc. (NYSE:IQV) is an analytical technology services and clinical research providing company headquartered in Durham, North Carolina. On September 6, 2022, IQVIA Holdings Inc. (NYSE:IQV) stock closed at $209.66 per share. IQVIA Holdings Inc. (NYSE:IQV) had a return of -12.53% for the past month and its shares lost 19.95% of their value in the last 52 weeks. IQVIA Holdings Inc. (NYSE:IQV) has a market capitalization of $39.103 billion.

Here is what L1 Capital International specifically said about IQVIA Holdings Inc. (NYSE:IQV) in its Q2 2022 investor letter:

IQVIA Holdings Inc. (NYSE:IQV) is the leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. Behind many of the breakthroughs in the treatment of COVID-19 you will find IQVIA. It is the largest contract research organisation (CRO) globally, planning and managing clinical trials as well as reporting on safety and efficacy in the real world following regulatory approval. IQVIA is not the life science industry gold miner, but rather provides the ‘picks and shovels’ to support others discover life sciences industry gold.

Few companies can compete with IQVIA – a proprietary database of over 1.2 billion non-identified patient records, a global healthcare IT network that receives and processes 100 billion healthcare records annually while ensuring privacy and security, combined with unique technology, data analytics and logistical capabilities managed by 80,000 employees in over 100 countries. IQVIA delivers information and insights on over 85% of the world’s pharmaceuticals, as measured by global sales. Disruption risk to this highly specialised but comprehensive network is limited.

A total addressable market assessed at over US$200 billion growing mid to high single digits per annum across IQVIA’s range of services ensures IQVIA has an extensive runway for growth…” (Click here to read the full text)

Tonhom1009/Shutterstock.com

IQVIA Holdings Inc. (NYSE:IQV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 53 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the second quarter which was 62 in the previous quarter.

We discussed IQVIA Holdings Inc. (NYSE:IQV) in another article and shared investment management company Ave Maria’s views on the company. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.

Disclosure: None. This article is originally published at Insider Monkey.